According to Phipps, the drugs currently available to treat Alzheimer’s have only eased the symptoms rather than stop its ...

Anavex Life Sciences' ANAVEX 2-73 shows promise in treating Alzheimer's, with strong efficacy in slowing cognitive and ...

Plasma p-tau217 immunoassay offers accurate detection of Alzheimer’s disease pathology, supporting early diagnosis and ...

This review provides an overview of Alzheimer’s disease (AD), discussing its complex pathophysiology, risk factors, and ...

Early research links the human cytomegalovirus, a type of herpes virus found in the gut, to the development of Alzheimer’s ...

Study to assess ability of GAL-101 eye drops in slowing or stopping the growth of geographic atrophy, a severe form of age-related macular ...

新型生物标志物的发现和新型治疗药物的问世， 标志着阿尔茨海默病在诊断与治疗方面有了突破性的进展 ，相信在未来的临床研究中可能会发现准确性更高的生物标志物和疗效更确切、不良反应更少、更加便捷的药物，从而 延缓阿尔茨海默病的病情进展及改善患者的生活质量 ...

In a deal worth $100 million up front and up to $1.25 billion in milestone payments, Bioarctic AB licensed its pyroglutamate-amyloid-β (pyroglutamate-Aβ) antibody program to Bristol Myers Squibb Co.

Prothena's stock soared 34% despite setbacks, with promising partnerships and potential in Parkinson's and Alzheimer's ...

Why is age the strongest risk factor for Alzheimer’s disease? In the December 10 Science Signaling ... As SIRT6 peters out, more APP remains to generate Aβ peptides. Indeed, co-first authors Bai and ...

BioArctic's PyroGlu-Aβ antibody program consists of novel antibodies targeting a specific truncated, pyroglutamate modified form of amyloid-beta. Monomers of PyroGlu-Aβ are highly prone to aggregate, ...

Improvements Across Measures of Behavior, Function, Cognition and Movement -- Expediting Plans to Advance CT1812 into Late-Stage Trials -- Full ...